Bone Metastases, Pathological Fracture of Hip
Conditions
Keywords
Osteosynthesis, Prophylactic consolidation, Proximal femur
Brief summary
HIPPON 100 is a national, multicentre, prospective, retrospective, descriptive and non-interventional study, in patients having a Y-STRUT® medical device implanted to prevent a high risk of impending pathological fracture. The primary objective of this study is to evaluate the performance of the studied medical device by measuring the frequency of patient with a fracture at the implantation site within 1 year after implantation. A total of 100 patients from France will be enrolled (until November 2018) and followed up to 24 months.
Interventions
The studied medical device consists of two components implanted in the proximal femur, combined with bone cement.
Sponsors
Hyprevention
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient ≥ 18 years old * Patient with information form signed to participate in the study; * Patient presenting a cancer with bone metastases at the level of the proximal femur and having a Y-STRUT® medical device implanted; * Patient able to complete a questionnaire.
Exclusion criteria
* Patient who refuse to participate to this study; * Patient already enrolled in a clinical study, excluding his participation to HIPPON100.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Frequency of post-operative fracture [Performance of the device] | At 12 months | Frequency of patient with a fracture at the implantation site |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pain [Tolerance of the device] | immediate post-op, and at 6, 12 and 24 months | Self-evaluation of pain using VAS (Visual Analogue Scale), going from 0 (no pain) to 10 (maximum). |
| Resumption of weight-bearing [Tolerance of the device] | immediate post-op, and at 6, 12 and 24 months | Assessment of resumption of weight-bearing (yes/no at each visit) |
| Quality of life [Tolerance of the device] | pre-operative, immediate post-op, and at 6, 12 and 24 months | Assessment of the quality of life using EORTC QLQ-C15-PAL questionnaire: the European Organization for Research and Treatment of Cancer (EORTC) has developed the QLQ-C15-PAL questionnaire (quality of life questionnaire with 15 items), a short version of the QLQ-C30 for palliative (PAL) care. Scale ranges go from 15 (better) to 63 points (worse) at the maximum. |
| Recording of adverse events and device effects [Safety of the device] | At 6, 12 and 24 months | Recording of the medical device vigilance: all serious adverse events, all adverse events linked to the device or the operative technique, and any other important event reported. |
| Frequency of post-operative fracture [Performance of the device] | At 6 and 24 months | Frequency of patient with a fracture at the implantation site |
| Hospitalisation duration [feasibility of the procedure] | At inclusion (day 1) | Measuring mean/median hospitalisation duration. |
| Rates of complications [feasibility of the procedure] | At inclusion (day 1) | Assessing types and frequencies of procedures complications. |
| Calculation of associated costs [Economic impact of the procedure] | At the end of the study (24 months from the last included patient) | Evaluation of each cost associated with all the collected data linked to the procedure (implantation costs, hospitalisation costs, treatments for pain and other events). Then, the different costs are added together to determine the mean total cost of a procedure. |
| Surgical procedure duration [feasibility of the procedure] | At inclusion (day 1) | Measuring mean/median intervention duration. |
Countries
France
Outcome results
None listed